Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to a deferred bonus plan.
- Share Price: 1556.50 pence per Ordinary Share and $53.87 per ADS.
- Transaction Date: July 14, 2014 (Notification date following dividend reinvestment on July 10, 2014).
Material Changes
The filing details increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for various executives following the re-investment of dividends. No material changes to the company's financial position or operations are reported in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing confirms share acquisitions by senior management, including Sir Andrew Witty, under a deferred bonus plan.
- Acquisitions were made via personal contributions and matching company contributions.
- Notional dividends accrued will be paid out based on the percentage of holdings that vest after the relevant measurement period.
- This report does not contain financial performance data or strategic updates.